drugset / Trial / NCT00455767

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

NCT00455767 ↗

Phase 2 Completed 84 enrolled Debiopharm International SA
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress Syndrome.

Timeline

Start
2006-07
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Depelestat Unknown 1 mg/kg Intravenous